Drug Profile
Anbenitamab - Alphamab
Alternative Names: anti-HER2-bsAb - Alphamab; KN-026Latest Information Update: 18 Apr 2024
Price :
$50
*
At a glance
- Originator Alphamab
- Developer Jiangsu Alphamab Biopharmaceuticals
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Gastric cancer
- Phase II Breast cancer; HER2 positive breast cancer; Solid tumours
Most Recent Events
- 01 Dec 2023 Peking University and Jiangsu Alphamab Biopharmaceuticals completes a phase I trial in Solid tumours(Combination therapy, Late stage disease, Second line therapy or greater) in China (IV) (NCT04040699)
- 20 Oct 2023 Safety and efficacy data from a phase II trial in HER2-positive breast cancer presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)
- 20 Oct 2023 Updated efficacy and adverse event data from a phase II in HER2-positive breast cancer presented at the 48th European Society for Medical Oncology Congress 2023 (ESMO-2023)